Succinylcholine chloride product labeling
FDA Anesthetic & Life Support Drugs Advisory Committee will meet June 9 at 8:30 a.m. to discuss the labeling of short-acting muscle relaxant succinylcholine products marketed by Burroughs Wellcome (Anectine), Abbott Labs (Quelicin), Bristol-Myers Squibb (Sucostrin) and Organon. The committee may be revisiting its November 1992 suggestion to include a warning about the possibility of cardiac arrest in children with Duchenne's muscular dystrophy ("The Pink Sheet" Nov. 30, 1992, p. 11). The committee also will discuss occurrence of loss of sensation and motor function due to possible nerve damage associated with administration of Astra's Xylocaine-MPF 5% lidocaine injection with glucose 7.5% for spinal anesthesia. On June 10, from 8 to 9 a.m., the panel will be presented with a progress report on studies of the metabolism of lidocaine by human liver tissues. Closed committee deliberations will follow. The meeting will take place at FDA's Parklawn Building, conference rooms D & E
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth